Investor Presentation Full Year 2021
30
Investor presentation
Full year 2021
Novo NordiskⓇ
Pipeline supports significant growth opportunities across all four
strategic focus areas
PHASE 1
NN1965 - Insulin 945
NN1845 - GSI
NN1471 - Ideal Pump Insulin
NN9041 - DNA Immunotherapy
NN9215
LA-GDF15
NN9838 Cagrisema
NN7533 Eclipse
NN6434 PCSK9i
-
NN6019 PR0004 ATTR Cardiomypathy
NN-TBD DCR-AUD
Diabetes care
PHASE 2
NN9388
-
Cagrisema
NN9389 FDC Sema - OW GIP
NN9838 Cagrilintide
NN9775 PYY 1875 analogue
-
NN9931 Gilead NASH
-
NN9500 FGF-21 NASH
NN6435 Oral PCSK9i
NN-TBD Belcesiran
Obesity care
PHASE 3
NN1535 Icosema
―
NN9924 Oral Semaglutide 25 and 50 mg
NN1436 Icodec
-
NN9932 Oral Semaglutide 50mg obesity
NN9931 Semaglutide NASH
NN6535 Semaglutide in AD
NN6018 Ziltivekimab
EX2020 Macimorelin, GHD¹
NN8640 Sogroya® - QW GHD2
NN-TBD - Nedosiran
NN7415 Concizumab
NN7769 Mim8
Other PHASE 3 trials
SOUL - Oral Semaglutide 14.0 mg CVOT
FLOW-Semaglutide 1.0 mg in chronic kidney
disease
FOCUS - Semaglutide 1.0 mg in diabetic retinopathy
STRIDE - Semaglutide 1.0 mg in peripheral arterial
disease
SELECT
Semaglutide 2.4 mg in obesity CVOT
HFPEF Semaglutide 2.4 mg
Rare blood disorders
APPROVED
SUBMITTED
SUSTAIN FORTE - Semaglutide 2.0
mg3
TresibaⓇ
XultophyⓇ
LevemirⓇ
Ryzodeg
Ⓡ
NovoMixⓇ
FiaspⓇ
Rare endocrine disorders
NovoRapidⓇ
RybelsusⓇ
OzempicⓇ®4
VictozaⓇ
WegovyⓇ4
SaxendaⓇ
NovoSevenⓇ
Novo Eight®
EsperoctⓇ
NovoThirteenⓇ
Refixia /RebinynⓇ
NorditropinⓇ
SogroyaⓇ5
Other serious chronic diseases
1 Novo Nordisk only holds the commercial rights in North America; 2 Study conducted in growth hormone disorders; 3 Approved in the EU and submitted the US (Resubmitted on 28 May 2021); 4 includes sema 2.0 mg; 5 Approved in the EU, the US and Japan, for
adult growth hormone disorder; PYY: Peptide YY; mAb: monocolonal antibody; GDF15: Growth differentiation factor 15; Sema: Semaglutide; FGF-21: Fibroblast growth factor 21; GHD: Growth hormone disorder; GSI: Glucose Sensitive Insulin; HFPEF: heart
failure with preserved ejection fraction; AD: Alzheimer's Disease; FDC; Fixed-dose combination; NASH: Nonalcoholic Steatohepatitis; AUD: Alcohol use disorder
TBD: NN Project IDs are pending for the assets Nedosiran, Belcesiran, DCR-AUDView entire presentation